Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436–6446.
53.
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256–4265.
54.
Kim D, Sarbassov D, Ali S, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163–175.
55.
Frias M, Thoreen C, Jaffe J, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 2006;16:1865–1870.
56.
Lander ES, Linton LM, Birren B, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921. Erratum in: Nature 2001;412:565; Nature 2001;411:720.
57.
Chan EK, Rowe HC, Hansen BG, et al. The complex genetic architecture of the metabolome. PLoS Genet 2010;6:e1001198.
58.
Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad SciUSA 1971;68:820–823.
59.
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789–799.
60.
Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003;21:4364–4370.
61.
King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–646.
62.
Sherr CJ. Principles of tumor suppression. Cell 2004;116:235–246.
63.
Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003;97:389–404.
64.
Drake AC, Campbell H, Porteous ME, et al. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer 2003;13:262–277.
65.
Baker VV. Update on the molecular carcinogenesis of cervix cancer. Clin Consult Obstet Gynecol 1995;7:86–93.
66.
Hogdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66–73.
67.